Skip to content

Early Feasibility Study of Transcutaneous Upper Airway Stimulation in Obstructive Sleep Apnea

Early Feasibility Study of Transcutaneous Upper Airway Stimulation in Obstructive Sleep Apnea

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05881512
Enrollment
12
Registered
2023-05-31
Start date
2022-09-12
Completion date
2023-02-22
Last updated
2023-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea, OSA

Brief summary

Early feasibility study to estimate the functionality of a novel intervention based on non-invasive transcutaneous electrical stimulation of the hypoglossal nerve to reduce the Apnea Hypopnea Index (AHI).

Interventions

DEVICETranscutaneous Upper Airway Stimulation Device

Multiple frequency stimulation of the hypoglossal nerve

Sponsors

Somnial Inc
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, aged 18 years or older * In good general health, as evidenced by medical history and diagnosed with moderate or severe OSA * In-lab PSG, within the last 6 months, with an AHI of 15-50/hour. In addition, \<25% of the respiratory events on the diagnostic PSG can be attributed to central apneas * BMI less than or equal to 32

Exclusion criteria

* No or mild OSA (AHI \<15/h) or very severe OSA (AHI \>50/hour), exclusively postural sleep apnea, or isolated Rapid-Eye-Movement (REM) sleep associated OSA. * Patients who are cachectic (BMI \<18.5 kg/m2) or obese (BMI \>32 kg/m2). * Patients should not have enlarged tonsils (size 3-4) and/or adenoids, nasal polyps, neuromuscular disease, hypoglossal nerve palsy, abnormal pulmonary function tests, severe pulmonary hypertension, valvular heart disease, heart failure (New York Heart Association, NYHA III-IV), recent myocardial infarction, significant cardiac arrhythmias, atrial fibrillation, stroke, opioid usage, uncontrolled hypertension, known allergic reaction to adhesives or latex, active psychiatric disease, co-existing non-respiratory sleep disorder, pregnancy or significant metal implants or cardiac/other pacemakers. * Patients with facial hair that affects the correct placement of the electrodes, if they are unwilling to shave.

Design outcomes

Primary

MeasureTime frameDescription
Apnea Hypopnea IndexOvernight (day 1)Episodes of apnea and/or hypopnea scored during the course of sleep study

Secondary

MeasureTime frameDescription
Arterial Oxygen Saturation (SaO2)Overnight (day 1)SaO2 levels during the course of sleep study compared to baseline

Other

MeasureTime frameDescription
Sleep QualityOvernight (day 1)Subjective Questionnaire

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026